Adjuvant Pembrolizumab Continues to Provide Survival Benefit in Stage IIB/C Melanoma
Source: OncLive, June 2023
Pembrolizumab (Keytruda) led to sustained improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) vs placebo as adjuvant therapy in patients with resected stage IIB or IIC melanoma, according to updated data from the phase 3 KEYNOTE-716 trial (NCT03553836) presented at the 2023 ASCO Annual Meeting.
At a median follow up of 39.4 months, 117 RFS events were seen with pembrolizumab and 174 events with placebo. Patients had a 36-month RFS rate of 76.2% with pembrolizumab vs 63.4% with placebo (HR, 0.62; 95% CI, 0.49-0.78).
At the time of median follow-up, there were 193 DMFS events in the overall population (n = 976). This consisted of 74 events with pembrolizumab, and 199 events with placebo (HR, 0.59; 95% CI, 0.44-0.79). The 36-month DMFS rate was 84.4% with pembrolizumab vs 74.7% with placebo. Median DMFS was not reached in either arm.